Scholarlink

Background <p>Semaglutide, a glucagon-like peptide-1 receptor agonist widely used in diabetes management, has not been previously reported to interfere with PET/CT imaging. This case highlights a novel observation regarding same-day subcutaneous semaglutide injection leading to increased muscular <sup>18</sup>F-FDG uptake, which compromises lesion detectability.</p> Case presentation <p>A 48-year-old male with diabetes presented with “right ear fluid outflow” and underwent a baseline PET/CT scan without recent semaglutide, showing focal uptake in the nasopharynx and lymph nodes without muscular interference. Thirteen months later, he returned with lower back pain. A repeat PET/CT performed on the same day as semaglutide injection showed diffusely elevated muscle uptake, obscuring potential lesions. After discontinuing semaglutide for 6 days, a third scan revealed normalized muscular activity and clear visualization of multiple hypermetabolic lesions.</p> Conclusions <p>This is the first report indicating that same-day semaglutide administration can significantly reduce PET/CT image quality by increasing muscle FDG uptake. Clinicians should consider discontinuing semaglutide at least 24&#xa0;h prior to PET/CT in diabetic patients to ensure diagnostic accuracy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Subcutaneous injection of semaglutide causes increased muscle uptake of 18F-FDG and reduces the imaging quality of PET/CT: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月12日

查看全文
  • Dong-chun Hong,
  • Liyuan Le,
  • Weipeng Chen,
  • Wen Long,
  • Wei Fan

摘要

Background

Semaglutide, a glucagon-like peptide-1 receptor agonist widely used in diabetes management, has not been previously reported to interfere with PET/CT imaging. This case highlights a novel observation regarding same-day subcutaneous semaglutide injection leading to increased muscular 18F-FDG uptake, which compromises lesion detectability.

Case presentation

A 48-year-old male with diabetes presented with “right ear fluid outflow” and underwent a baseline PET/CT scan without recent semaglutide, showing focal uptake in the nasopharynx and lymph nodes without muscular interference. Thirteen months later, he returned with lower back pain. A repeat PET/CT performed on the same day as semaglutide injection showed diffusely elevated muscle uptake, obscuring potential lesions. After discontinuing semaglutide for 6 days, a third scan revealed normalized muscular activity and clear visualization of multiple hypermetabolic lesions.

Conclusions

This is the first report indicating that same-day semaglutide administration can significantly reduce PET/CT image quality by increasing muscle FDG uptake. Clinicians should consider discontinuing semaglutide at least 24 h prior to PET/CT in diabetic patients to ensure diagnostic accuracy.